{"entity":{"id":"nct05488314","kind":"trial","name":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of Capmatinib and Amivantamab in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","summary":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT05488314 by Janssen Research & Development, LLC, with 57 participants enrolled, started 2022-12-13 and due to reach its primary completion in 2027-04-28. Interventions recorded: Capmatinib and Amivantamab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05488314","url":"https://clinicaltrials.gov/study/NCT05488314"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["capmatinib","amivantamab"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05488314","phase":"1/2","setting":"A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","sponsor":"Janssen Research & Development, LLC","enrolled":57,"outcomes":[]},"route":"/trials/nct05488314/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/"},{"id":"capmatinib","kind":"drug","name":"Capmatinib","route":"/drugs/capmatinib/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}